05 Aug 2024
// PRESS RELEASE
15 Jul 2024
// PRESS RELEASE
15 Jul 2024
// PRESS RELEASE
Latest Content by PharmaCompass
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
About
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
CPHI Middle eastCPHI Middle east
Industry Trade Show
Not Confirmed
10-12 December, 2024
Medlab Asia & Asia Hea...Medlab Asia & Asia Health
Industry Trade Show
Not Confirmed
24 November-17 July, 2025
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
02-04 December, 2024
CONTACT DETAILS
Events
Webinars & Exhibitions
CPHI Middle eastCPHI Middle east
Industry Trade Show
Not Confirmed
10-12 December, 2024
Medlab Asia & Asia Hea...Medlab Asia & Asia Health
Industry Trade Show
Not Confirmed
24 November-17 July, 2025
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
02-04 December, 2024
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
05 Aug 2024
// PRESS RELEASE
https://www.aartipharmalabs.com/investors/audited-financial-statements-for-the-quarter-ended-june-30-2024.pdf
15 Jul 2024
// PRESS RELEASE
15 Jul 2024
// PRESS RELEASE
14 May 2024
// BUSINESS-STANDARD
https://www.business-standard.com/markets/capital-market-news/aarti-pharmalabs-jumps-after-q4-pat-climbs-52-yoy-to-rs-65-cr-124051400192_1.html
13 May 2024
// PRESS RELEASE
https://www.aartipharmalabs.com/investors/audited-financial-statements-for-the-year-ended-march-31-2024.pdf
07 Feb 2024
// PRESS RELEASE
https://www.aartipharmalabs.com/investors/audited-financial-statements-for-the-quarter-ended-december-31-2023.pdf